Clear cell renal cell carcinoma

identifying the gain of chromosome 12 on multiphasic MDCT

Jonathan R Young, Heidi Coy, Michael Douek, Pechin Lo, James Sayre, Allan J. Pantuck, Steven S. Raman

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: To determine whether multiphasic MDCT enhancement can help identify the gain of chromosome 12 in clear cell renal cell carcinomas (RCCs). Methods: With IRB approval for this HIPAA-compliant case control study, we derived a cohort of 65 clear cell RCCs with preoperative four-phase renal mass MDCT from October 2000 to August 2013. Each lesion was segmented in its entirety on axial images in all phases. A computer-assisted detection (CAD) algorithm selected a 0.5-cm-diameter region of maximal attenuation within each lesion in each phase. Attenuation in each phase between clear cell RCCs with and without the gain of 12 was compared using t-tests. Results: While the entire cohort of clear cell RCCs exhibited peak enhancement in the corticomedullary phase, the subcohort of lesions with the gain of 12 exhibited significantly greater enhancement in the nephrographic (179 vs. 145 HU, p = 0.004) and excretory phases (147 vs. 118 HU, p = 0.004) than the subcohort of lesions without the gain of 12. A nephrographic threshold of 186 HU identified the gain of 12 with an accuracy of 86% (56/65), specificity of 93% (51/55), and negative predictive value of 91% (51/56). Conclusion: Multiphasic MDCT enhancement, specifically enhancement in the nephrographic and excretory phases, may potentially assist in identifying the gain of 12 in clear cell RCCs.

Original languageEnglish (US)
Pages (from-to)236-241
Number of pages6
JournalAbdominal Radiology
Volume42
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Chromosomes, Human, Pair 12
Renal Cell Carcinoma
Health Insurance Portability and Accountability Act
Research Ethics Committees
Case-Control Studies
Kidney

Keywords

  • Clear cell renal cell carcinoma
  • Cytogenetics
  • Multidetector computed tomography
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging
  • Gastroenterology
  • Urology

Cite this

Clear cell renal cell carcinoma : identifying the gain of chromosome 12 on multiphasic MDCT. / Young, Jonathan R; Coy, Heidi; Douek, Michael; Lo, Pechin; Sayre, James; Pantuck, Allan J.; Raman, Steven S.

In: Abdominal Radiology, Vol. 42, No. 1, 01.01.2017, p. 236-241.

Research output: Contribution to journalArticle

Young, Jonathan R ; Coy, Heidi ; Douek, Michael ; Lo, Pechin ; Sayre, James ; Pantuck, Allan J. ; Raman, Steven S. / Clear cell renal cell carcinoma : identifying the gain of chromosome 12 on multiphasic MDCT. In: Abdominal Radiology. 2017 ; Vol. 42, No. 1. pp. 236-241.
@article{efa0c1f95b054e7eba3a02e201d3883a,
title = "Clear cell renal cell carcinoma: identifying the gain of chromosome 12 on multiphasic MDCT",
abstract = "Purpose: To determine whether multiphasic MDCT enhancement can help identify the gain of chromosome 12 in clear cell renal cell carcinomas (RCCs). Methods: With IRB approval for this HIPAA-compliant case control study, we derived a cohort of 65 clear cell RCCs with preoperative four-phase renal mass MDCT from October 2000 to August 2013. Each lesion was segmented in its entirety on axial images in all phases. A computer-assisted detection (CAD) algorithm selected a 0.5-cm-diameter region of maximal attenuation within each lesion in each phase. Attenuation in each phase between clear cell RCCs with and without the gain of 12 was compared using t-tests. Results: While the entire cohort of clear cell RCCs exhibited peak enhancement in the corticomedullary phase, the subcohort of lesions with the gain of 12 exhibited significantly greater enhancement in the nephrographic (179 vs. 145 HU, p = 0.004) and excretory phases (147 vs. 118 HU, p = 0.004) than the subcohort of lesions without the gain of 12. A nephrographic threshold of 186 HU identified the gain of 12 with an accuracy of 86{\%} (56/65), specificity of 93{\%} (51/55), and negative predictive value of 91{\%} (51/56). Conclusion: Multiphasic MDCT enhancement, specifically enhancement in the nephrographic and excretory phases, may potentially assist in identifying the gain of 12 in clear cell RCCs.",
keywords = "Clear cell renal cell carcinoma, Cytogenetics, Multidetector computed tomography, Renal cell carcinoma",
author = "Young, {Jonathan R} and Heidi Coy and Michael Douek and Pechin Lo and James Sayre and Pantuck, {Allan J.} and Raman, {Steven S.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/s00261-016-0868-7",
language = "English (US)",
volume = "42",
pages = "236--241",
journal = "Abdominal Radiology",
issn = "2366-004X",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Clear cell renal cell carcinoma

T2 - identifying the gain of chromosome 12 on multiphasic MDCT

AU - Young, Jonathan R

AU - Coy, Heidi

AU - Douek, Michael

AU - Lo, Pechin

AU - Sayre, James

AU - Pantuck, Allan J.

AU - Raman, Steven S.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose: To determine whether multiphasic MDCT enhancement can help identify the gain of chromosome 12 in clear cell renal cell carcinomas (RCCs). Methods: With IRB approval for this HIPAA-compliant case control study, we derived a cohort of 65 clear cell RCCs with preoperative four-phase renal mass MDCT from October 2000 to August 2013. Each lesion was segmented in its entirety on axial images in all phases. A computer-assisted detection (CAD) algorithm selected a 0.5-cm-diameter region of maximal attenuation within each lesion in each phase. Attenuation in each phase between clear cell RCCs with and without the gain of 12 was compared using t-tests. Results: While the entire cohort of clear cell RCCs exhibited peak enhancement in the corticomedullary phase, the subcohort of lesions with the gain of 12 exhibited significantly greater enhancement in the nephrographic (179 vs. 145 HU, p = 0.004) and excretory phases (147 vs. 118 HU, p = 0.004) than the subcohort of lesions without the gain of 12. A nephrographic threshold of 186 HU identified the gain of 12 with an accuracy of 86% (56/65), specificity of 93% (51/55), and negative predictive value of 91% (51/56). Conclusion: Multiphasic MDCT enhancement, specifically enhancement in the nephrographic and excretory phases, may potentially assist in identifying the gain of 12 in clear cell RCCs.

AB - Purpose: To determine whether multiphasic MDCT enhancement can help identify the gain of chromosome 12 in clear cell renal cell carcinomas (RCCs). Methods: With IRB approval for this HIPAA-compliant case control study, we derived a cohort of 65 clear cell RCCs with preoperative four-phase renal mass MDCT from October 2000 to August 2013. Each lesion was segmented in its entirety on axial images in all phases. A computer-assisted detection (CAD) algorithm selected a 0.5-cm-diameter region of maximal attenuation within each lesion in each phase. Attenuation in each phase between clear cell RCCs with and without the gain of 12 was compared using t-tests. Results: While the entire cohort of clear cell RCCs exhibited peak enhancement in the corticomedullary phase, the subcohort of lesions with the gain of 12 exhibited significantly greater enhancement in the nephrographic (179 vs. 145 HU, p = 0.004) and excretory phases (147 vs. 118 HU, p = 0.004) than the subcohort of lesions without the gain of 12. A nephrographic threshold of 186 HU identified the gain of 12 with an accuracy of 86% (56/65), specificity of 93% (51/55), and negative predictive value of 91% (51/56). Conclusion: Multiphasic MDCT enhancement, specifically enhancement in the nephrographic and excretory phases, may potentially assist in identifying the gain of 12 in clear cell RCCs.

KW - Clear cell renal cell carcinoma

KW - Cytogenetics

KW - Multidetector computed tomography

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84982168594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982168594&partnerID=8YFLogxK

U2 - 10.1007/s00261-016-0868-7

DO - 10.1007/s00261-016-0868-7

M3 - Article

VL - 42

SP - 236

EP - 241

JO - Abdominal Radiology

JF - Abdominal Radiology

SN - 2366-004X

IS - 1

ER -